https://www.mypharma-editions.com/cellectis-bioresearch-et-lonza-accord-de-developpement-et-de-commercialisation-de-lignees-cellulaires
Cellectis bioresearch et Lonza : accord de développement et de commercialisation de lignées...
Jun 9, 2010 - Cellectis bioresearch, spécialiste de la personnalisation des génomes et filiale commerciale de Cellectis, et Lonza, un leader mondial de la production...
cellectisbioresearchlonzaaccordcommercialisation
https://www.cellectis.com/en/press/page/2/
Press releases | Cellectis
Jun 25, 2026 - Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer.
press releasescellectis
https://www.cellectis.com/en/investors/governance-documents/2026/
Governance Documents | Cellectis
Jun 25, 2026 - Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer.
governance documentscellectis
https://www.cellectis.com/fr/evenements/
Evénements | Cellectis
Sep 11, 2026 - Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer.
cellectis
https://www.africanewscurrents.com/article/910333377-cellectis-to-report-first-quarter-financial-results-on-may-11-2026
Cellectis to Report First Quarter Financial Results on May 11, 2026 | Africa News Currents
Africa News Currents is an online news publication focusing on the Africa: Your daily news update on Africa
first quarterfinancial resultsafrica newscellectisreport
https://www.healthtimesrhodeisland.com/article/930623846-cellectis-to-report-second-quarter-financial-results-on-august-6-2026
Cellectis to Report Second Quarter Financial Results on August 6, 2026 | Health Times of Rhode...
second quarterfinancial resultscellectisreportaugust
https://www.scitechnorthernmarianaislands.com/article/918499463-cellectis-re-oit-le-statut-rmat-de-la-fda-pour-lasm-cel-la-premi-re-th-rapie-car-t-allog-nique-en-essai-pivot-pour-les-patients-atteints-de-lla-b-en
Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en...
de lacellectisstatutrmatfda
https://www.cellectis.com/en/press/2023/
Press releases | Cellectis
Jun 25, 2026 - Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer.
press releasescellectis
https://www.palauhealthcaretimes.com/article/875890688-cellectis-announces-arbitral-decision-in-dispute-with-servier
Cellectis Announces Arbitral Decision in Dispute with Servier | Palau Healthcare Times
cellectisannouncesarbitraldecisiondispute
Sponsored https://ctwmsg.com/?siteId=jasmin&cobrandId=&superCategoryName=&categoryName=mature&pageName=listpage&prm[psid]=robuta&prm[pstool]=211_15&prm[psprogram]=pps&prm[campaign_id]=&subAffId=
Live Sex Cams and Adult Chat with Webcam Girls | LiveJasmin
Chat for free on LiveJasmin and watch HD Live Sex cam shows! 2000+ Models are waiting for You, no registration required.
https://www.cellectis.com/en/press/cellectis-provides-business-update-and-reports-financial-results-for-second-quarter-and-first-six-months-2021/
Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six...
Aug 6, 2026 - Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed or refractory multiple myeloma patients. Preclinical pipeline...
financial resultssecond quartercellectisprovidesbusiness